JP2022523301A5 - - Google Patents

Info

Publication number
JP2022523301A5
JP2022523301A5 JP2021543226A JP2021543226A JP2022523301A5 JP 2022523301 A5 JP2022523301 A5 JP 2022523301A5 JP 2021543226 A JP2021543226 A JP 2021543226A JP 2021543226 A JP2021543226 A JP 2021543226A JP 2022523301 A5 JP2022523301 A5 JP 2022523301A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
angptl7
position corresponding
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523301A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014373 external-priority patent/WO2020154268A2/en
Publication of JP2022523301A publication Critical patent/JP2022523301A/ja
Publication of JP2022523301A5 publication Critical patent/JP2022523301A5/ja
Priority to JP2024213170A priority Critical patent/JP2025023307A/ja
Pending legal-status Critical Current

Links

JP2021543226A 2019-01-23 2020-01-21 アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療 Pending JP2022523301A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213170A JP2025023307A (ja) 2019-01-23 2024-12-06 アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962795665P 2019-01-23 2019-01-23
US62/795,665 2019-01-23
US201962880609P 2019-07-30 2019-07-30
US62/880,609 2019-07-30
US201962902683P 2019-09-19 2019-09-19
US62/902,683 2019-09-19
US201962909573P 2019-10-02 2019-10-02
US62/909,573 2019-10-02
PCT/US2020/014373 WO2020154268A2 (en) 2019-01-23 2020-01-21 Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213170A Division JP2025023307A (ja) 2019-01-23 2024-12-06 アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療

Publications (2)

Publication Number Publication Date
JP2022523301A JP2022523301A (ja) 2022-04-22
JP2022523301A5 true JP2022523301A5 (cg-RX-API-DMAC7.html) 2023-01-30

Family

ID=69591771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543226A Pending JP2022523301A (ja) 2019-01-23 2020-01-21 アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療
JP2024213170A Pending JP2025023307A (ja) 2019-01-23 2024-12-06 アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213170A Pending JP2025023307A (ja) 2019-01-23 2024-12-06 アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療

Country Status (11)

Country Link
US (2) US11767526B2 (cg-RX-API-DMAC7.html)
EP (1) EP3914711A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022523301A (cg-RX-API-DMAC7.html)
KR (1) KR20210132045A (cg-RX-API-DMAC7.html)
CN (1) CN113646432A (cg-RX-API-DMAC7.html)
AU (1) AU2020210630C1 (cg-RX-API-DMAC7.html)
CA (1) CA3126476A1 (cg-RX-API-DMAC7.html)
IL (1) IL284700B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021008797A (cg-RX-API-DMAC7.html)
SG (1) SG11202107497XA (cg-RX-API-DMAC7.html)
WO (1) WO2020154268A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
CA3126476A1 (en) 2019-01-23 2020-07-30 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
JP2022535717A (ja) 2019-05-24 2022-08-10 エンピリコ インク. アンジオポエチン様7(angptl7)関連疾患の処置
WO2022072356A1 (en) * 2020-09-29 2022-04-07 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
WO2022115383A1 (en) * 2020-11-24 2022-06-02 Empirico Inc. Treatment of sos2 related diseases and disorders
WO2022182768A1 (en) * 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
CN116997653A (zh) * 2021-02-26 2023-11-03 雷杰纳荣制药公司 用糖皮质激素和血管生成素样7(angptl7)抑制剂治疗炎症
KR20240099232A9 (ko) * 2021-09-30 2025-12-10 리제너론 파마슈티칼스 인코포레이티드 Rho 구아닌 뉴클레오타이드 교환 인자 12[Rho Guanine Nucleotide Exchange Factor 12, ARHGEF12] 억제제를 이용한 녹내장 치료
JP2024538646A (ja) * 2021-10-01 2024-10-23 アルナイラム ファーマシューティカルズ, インコーポレイテッド ANGPTL7を標的化するためのiRNA組成物および方法
EP4453210A1 (en) * 2021-12-22 2024-10-30 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1781787T3 (en) 2004-08-23 2017-07-31 Sylentis Sau TREATMENT OF EYE DISORDERS FEATURED BY AN INCREASED INTRAOCULAR PRESSURE WITH SIRNAS
EP2035576A4 (en) 2006-07-05 2010-09-08 Orientbio Co Ltd METHOD OF CANCER DIAGNOSIS BY DETERMINING THE METHYLATION OF TRANSITION ZONES
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
WO2011051276A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Colon and rectal tumor markers and methods of use thereof
US9551034B2 (en) 2010-01-11 2017-01-24 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2397559A1 (en) 2010-06-17 2011-12-21 Max-Delbrück-Centrum Für Molekulare Medizin Stage-specific biomarkers for the diagnosis of acute kidney injury
US20120010230A1 (en) 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
TWI534152B (zh) 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
PL2710375T3 (pl) 2011-05-18 2019-07-31 Baxalta GmbH Testy aktywności zależne od modyfikacji
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US20130310546A1 (en) 2012-05-16 2013-11-21 Bater Healthcare Sa Nucleophilic catalysts for oxime linkage and use of nmr analyses of the same
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
CA2884455A1 (en) 2012-09-21 2014-03-27 Integragen A new method for classification of liver samples and diagnosis of focal nodule dysplasia, hepatocellular adenoma, and hepatocellular carcinoma
US9206423B2 (en) * 2012-12-30 2015-12-08 The Regents Of The University Of California Methods of modulating compliance of the trabecular meshwork
WO2014167529A1 (en) 2013-04-10 2014-10-16 Institut De Cardiologie De Montreal Methods and compositions for preventing and treating atherosclerosis
WO2015132303A1 (en) * 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
WO2015179633A1 (en) 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
CA3005980A1 (en) 2015-11-24 2017-06-01 Commonwealth Scientific And Industrial Research Organisation Production of viruses in avian eggs
CN108603188A (zh) 2015-11-24 2018-09-28 联邦科学技术研究组织 在细胞培养物中产生病毒
CA3019635A1 (en) 2016-03-31 2017-10-05 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
JP7050215B2 (ja) 2016-08-19 2022-04-08 ツールゲン インコーポレイテッド 人工的に操作された血管新生調節系
SG10201913074WA (en) * 2016-08-30 2020-03-30 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
AU2017357072A1 (en) 2016-11-14 2019-05-30 Memorial Sloan-Kettering Cancer Center Stem cell derived schwann cells
WO2018174861A1 (en) 2017-03-21 2018-09-27 Mprobe Inc. Methods and compositions for detecting early stage breast cancer with rna-seq expression profiling
EP3600108A4 (en) 2017-03-23 2021-01-06 The Regents of the University of California STIMULATION OF HAIR GROWTH BY SENESCENCE CELLS AND SENESCENCE-ASSOCIATED SECRETORIC PHENOTYPE
JP2018164442A (ja) * 2017-03-28 2018-10-25 国立大学法人 熊本大学 皮膚有棘細胞癌の判定、予防又は治療方法
JP6779164B2 (ja) * 2017-03-28 2020-11-04 ヤンマーパワーテクノロジー株式会社 作業車両の自律走行システム
JP7493940B2 (ja) 2017-05-31 2024-06-03 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 鳥類における形質選択
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
EP3740224A4 (en) 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES
GB201806118D0 (en) 2018-04-13 2018-05-30 Univ Edinburgh Macrophage use
CA3126476A1 (en) 2019-01-23 2020-07-30 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
JP2022535717A (ja) 2019-05-24 2022-08-10 エンピリコ インク. アンジオポエチン様7(angptl7)関連疾患の処置
WO2022072356A1 (en) 2020-09-29 2022-04-07 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases

Similar Documents

Publication Publication Date Title
JP2008520242A5 (cg-RX-API-DMAC7.html)
US20100119474A1 (en) Chronic obstructive pulmonary disease susceptibility and related compositions and methods
JP2002272489A5 (cg-RX-API-DMAC7.html)
JP2023531935A5 (cg-RX-API-DMAC7.html)
JP2006521812A (ja) 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用
Greber-Platzer et al. Evidence against the current hypothesis of “gene dosage effects” of trisomy 21: ets-2, encoded on chromosome 21” is not overexpressed in hearts of patients with Down syndrome
JP2001333785A (ja) MxAタンパク質の多型遺伝子およびその使用
JP2024521754A5 (cg-RX-API-DMAC7.html)
JP2022525545A5 (cg-RX-API-DMAC7.html)
JP2022515838A5 (cg-RX-API-DMAC7.html)
JP2022525456A5 (cg-RX-API-DMAC7.html)
JP4398379B2 (ja) B型肝炎ウイルスの薬物抵抗性を識別する方法
JP2005507654A5 (cg-RX-API-DMAC7.html)
JP4242590B2 (ja) 慢性関節リウマチの疾患感受性遺伝子、及びその利用
JP2022525546A5 (cg-RX-API-DMAC7.html)
JP2022544393A (ja) マクロファージ刺激1受容体(mst1r)バリアント及びその使用
JP4145129B2 (ja) Pcrクランピング法
RU2021121850A (ru) Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7)
RU2023131494A (ru) Лечение цереброваскулярного заболевания с помощью агентов - белков-гомологов 3 нейрогенного локуса notch (notch3)
JP2024536001A5 (cg-RX-API-DMAC7.html)
RU2021122161A (ru) Лечение респираторных нарушений с помощью ингибиторов арахидонат 15-липоксигеназы (alox15)
JP3002115B2 (ja) ヒト急性および慢性を含む持続性ストレス負荷における細胞内HSP70mRNAの転写異常とその応用(新規ヒト細胞内SHSP70mRNAの転写発現とHSP70mRNA転写異常との応用)
RU2021129890A (ru) Лечение гипергликемии с помощью ингибиторов члена 5 семейства 39 транспортеров растворенных веществ (slc39a5)
JP2024535110A5 (cg-RX-API-DMAC7.html)
CN118265529A (zh) 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗